Results 241 to 250 of about 77,953 (304)
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li +9 more
wiley +1 more source
A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum. [PDF]
Folkesson E +16 more
europepmc +1 more source
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik +3 more
wiley +1 more source
Effect of Variability on Interferon-Gamma Release Assay Performance: A Quantitative Analysis. [PDF]
Min WK.
europepmc +1 more source
Synthetic Strategies for Activity‐Based Probes to Decode Ubiquitin‐Like Modifiers
ABSTRACT Ubiquitin‐like proteins (Ubls) such as SUMO, NEDD8, ISG15, URM1, UFM1, FAT10, ATG8/ATG12, and FUBI are essential regulators of cellular homeostasis, controlling processes from protein stability and trafficking to immune signaling and autophagy.
Saibal Chanda +5 more
wiley +1 more source
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović +11 more
wiley +1 more source
Evaluating Canada's initiative of enhanced screening for tuberculosis infection in migrants: Implementation lessons from Alberta. [PDF]
Heffernan C +3 more
europepmc +1 more source

